Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline by Ralston, S.H. (Stuart) et al.

579
Diagnosis andManagement of Paget’s Disease of Bone in
Adults: A Clinical Guideline
Stuart H Ralston,1 Luis Corral-Gudino,2 Cyrus Cooper,3,4 Roger M Francis,5 William D Fraser,6 Luigi Gennari,7
Nuria Gua~nabens,8 M Kassim Javaid,4 Robert Layﬁeld,9 Terence W O’Neill,10,11 R Graham G Russell,4,12
Michael D Stone,13 Keith Simpson,4 Diana Wilkinson,4 Ruth Wills,14 M Carola Zillikens,15
and Stephen P Tuck16,17
1Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
2Internal Medicine Department, Hospital Universitario Rıo Hortega, University of Valladolid, Valladolid, Spain
3MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
4Botnar Research Centre, Nufﬁeld Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, Oxford, UK
5Paget’s Association, Manchester, UK
6Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK
7Department of Medicine, Surgery, and Neurosciences, University of Siena, Siena, Italy
8Hospital Clinic, IDIBAPS, CiberEHD, University of Barcelona, Barcelona, Spain
9School of Life Sciences, University of Nottingham Medical School, Queen’s Medical Centre, Nottingham, UK
10Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, UK
11NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre,
Manchester, UK
12The Mellanby Centre for Bone Research, University of Shefﬁeld, Shefﬁeld, UK
13Bone Research Unit, University Hospital Llandough, Penarth, UK
14International Medical Press, London, UK
15Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
16Department of Rheumatology, The James Cook University Hospital, Middlesbrough, UK
17Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
ABSTRACT
An evidence-based clinical guideline for the diagnosis andmanagement of Paget’s disease of bone (PDB)was developed using GRADE
methodology, by a Guideline Development Group (GDG) led by the Paget’s Association (UK). A systematic review of diagnostic tests
and pharmacological and nonpharmacological treatment options was conducted that sought to address several key questions of
clinical relevance. Twelve recommendations and ﬁve conditional recommendationsweremade, but therewas insufﬁcient evidence to
address eight of the questions posed. The following recommendations were identiﬁed as the most important: 1) Radionuclide bone
scans, in addition to targeted radiographs, are recommended as a means of fully and accurately deﬁning the extent of metabolically
activedisease in patientswith PDB. 2) Serum total alkalinephosphatase (ALP) is recommended as a ﬁrst-line biochemical screening test
in combination with liver function tests in screening for the presence of metabolically active PDB. 3) Bisphosphonates are
recommended for the treatmentofbonepain associatedwith PDB. Zoledronic acid is recommendedas thebisphosphonatemost likely
togive a favorable pain response. 4) Treatment aimedat improving symptoms is recommendedover a treat-to-target strategy aimedat
normalizing total ALP in PDB. 5) Total hip or knee replacements are recommended for patients with PDBwhodevelop osteoarthritis in
whom medical treatment is inadequate. There is insufﬁcient information to recommend one type of surgical approach over another.
The guideline was endorsed by the European Calciﬁed Tissues Society, the International Osteoporosis Foundation, the American
Society of Bone andMineral Research, the Bone Research Society (UK), and the British Geriatric Society. The GDG noted that there had
been a lack of research on patient-focused clinical outcomes in PDB and identiﬁed several areas where further research was needed. ©
2019 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
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Introduction
Paget’s disease of the bone is a nonmalignant skeletaldisorder characterized by focal abnormalities in bone
remodeling at one (monostotic) or more (polyostotic) skeletal
sites. Almost any bone can be affected, but there is a
predilection for the pelvis, spine, femur, tibia, and skull.(1)
The main risk factors for PDB include increasing age, male sex,
and ethnic background.(2,3) The risk of developing PDB increases
with age, with an approximate doubling in incidence each
decade after the age of 50 years.(2) Paget’s is more common in
males (1.4:1)(2) and in certain ethnic groups.(3) Whites are most
commonly affected,(3) and the disease has been estimated to
affect about 1% of people over the age of 55 years in the United
Kingdom.(2) It is also common in other European countries such
as France, Spain, and Italy and in people of European descent
who have emigrated to other regions of the world, such as
Australia, New Zealand, the United States of America, and
Canada.(3) Paget’s disease is rare in Scandinavian countries, the
Indian subcontinent, and Asian countries. Archeological studies
of skeletal remains suggest that these differences in prevalence
could be consistent with PDB having arisen as the result of
genetic mutations that predispose to the disease in people from
North-West Europe many centuries ago, with spread to other
regions of the world through emigration.(4)
At a cellular level, PDB is characterized by increased
numbers and activity of osteoclasts coupled with an increase
in osteoblast activity.(5) Bone formation is increased but
disorganized, with formation of woven bone, which is
mechanically weak and subject to deformity and fracture.
The focal increases in osteoclast and osteoblast activity in PDB
are also accompanied by marrow ﬁbrosis and increased
vascularity of bone. The pathogenesis of PDB is incompletely
understood, but genetic factors play a key role. Many affected
individuals have a family history,(6,7) and an autosomal
dominant pattern of inheritance with incomplete penetrance
may be observed.(8–10) The most important susceptibility gene
for PDB is SQSTM1,(11,12) which encodes p62, a protein involved
in the nuclear factor kappa B (NF-kB) signaling pathway.(13)
Mutations in SQSMT1 have been identiﬁed in 40% to 50% of
familial cases and in 5% to 10% of patients who do not report
having a family history.(9,14,15) Most of the causal mutations
impair the ability of p62 to bind ubiquitin, and this leads to
activation of receptor activator of nuclear kappa B ligand
(RANKL)-induced NF-kB signaling with increased osteoclast
activity.(16) Rarely, familial PDB or PDB-like disorders may occur
in association with mutations in other genes.(17–19) In some of
these syndromes, PDB is part of a multisystem disorder
accompanied by myopathy and neurodegeneration.(20,21)
Several other common risk alleles have been identiﬁed
through genomewide association that increase susceptibility
to PDB but that in themselves are not causal.(22)
Environmental factors also play a role in PDB as evidenced by
the fact that reductions in prevalence and severity have been
observed inmany countries over the past 25 years, most marked
in regions that previously had a high prevalence.(3,23–29) In
keeping with this, the prevalence of osteosarcoma in adults (a
complication of PDB) has also declined in recent years.(30,31)
Various environmental triggers for PDB have been suggested,
including dietary calcium or vitamin D deﬁciency and exposure
to environmental toxins,(32,33) repetitive biomechanical loading
or skeletal trauma,(34,35) and slow virus infections.(36) The most
widely studied environmental factor is slow virus infection, and
over the years, measles,(36) respiratory syncytial virus,(37) and
canine distemper(38) have all been implicated and overexpres-
sion of measles virus nucleocapsids protein in experimental
models has been shown to increase bone remodeling.(39)
Attempts to detect evidence of paramyxovirus nucleic acids and
proteins in patient material have yielded conﬂicting results,
however,(40–47) and serological studies have found no evidence
of an enhanced immune response to paramyxoviruses in
PDB.(48) It has been reported that the nuclear inclusion bodies
that were identiﬁed in PDBmany decades ago and thought to be
measles virus nucleocapsids(36) are morphologically distinct
from measles on ultrastructural analysis.(43) Experimental
evidence has been gained to suggest that they may instead
be abnormal protein aggregates due to defects in the
autophagy pathway.(49)
Many of the clinical features and complications of PDB are
thought to be due to the abnormalities of bone remodeling
that are characteristic of the disease. The enlarged bones may
cause hearing loss, basilar invagination of the skull, obstructive
hydrocephalus, spinal canal stenosis, and paraplegia. The
increased vascularity of bone can result in excessive blood loss
should orthopedic surgery be required. It has been suggested
that in some cases, paraplegia may be due to a vascular “steal”
phenomenon, rather than direct compression of the spinal
cord by bone enlargement.(50) High-output cardiac failure due
to increased bone blood ﬂow has been reported but is
extremely rare.(51) The overall frequency with which compli-
cations occur in PDB is unknown because it has been estimated
that fewer than 10% of patients with X-ray evidence of PDB
come to medical attention.(2) In those that do present clinically,
bone pain is the most common symptom, which was reported
to occur in 73% of patients in a recent systematic review.(52)
The mechanisms of pain in PDB are incompletely understood.
Although pain in some patients is due to increased metabolic
activity, there is a weak correlation between the presence of
bone pain and metabolic activity in PDB, at least as reﬂected by
total ALP concentrations. For example, in the study of Reid and
colleagues,(53) 23 of 55 (41.8%) patients with a raised total ALP
did not experience bone pain. Similarly, in the PRISM study,(54)
635 patients had a raised ALP at the baseline visit but 295
(46.4%) of these individuals did not have bone pain. Aside from
pain, many other complications of PDB are recognized. In the
systematic review cited previously,(52) bone deformity was
present in 21.5% of patients at ﬁrst presentation, followed by
deafness (8.9%) and pathological fracture (8.5%). Osteoarthritis
is a common complication of PDB. An analysis of the UK
General Practice Research Database in 2002 revealed that
patients who have been diagnosed with PDB were more likely
to require hip arthroplasty for osteoarthritis compared with
age-matched controls (odds ratio [OR]¼ 3.1, 95% conﬁdence
interval [CI] 2.4–4.1).(2) Osteosarcoma is a rare complication of
PDB, which affects about 0.3% of patients.(2) It has a poor
prognosis even with aggressive treatment.(55) Giant cell tumor
(GCT) is a very rare complication in PDB. A systematic review
identiﬁed 117 cases of GCT associated with PDB that had been
reported in the literature worldwide.(56) In this series, there was
overrepresentation of people of Italian descent from the region
of Campania. A high proportion of patients from this region
who have GCT and PDB carry a speciﬁc missense mutation in
the ZNF678 gene.(57) In Italy, the prevalence of GCT
complicating PDB is estimated to be about 0.8% (L Gennari,
unpublished data) but is likely to be much lower in other
countries.
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Need for the guideline
The Paget Association and other supporting organizations
identiﬁed a need for a new guideline that was evidence based,
patient focused, and that considered all of the available
evidence. This guideline differs from previous guidelines
published on this subject(58–60) in that we considered both
pharmacological and nonpharmacological treatment options; in
that we had patient representation on the guideline develop-
ment group and sought feedback from patients in the peer-
review process; and in that we have provided information on the
key questions used to develop the guideline, as well as details of
the search strategy and numbers of publications that were
reviewed for each key question.
Remit of the guideline
The remit of the guideline was to provide patient-centered,
evidence-based recommendations for the diagnosis and
management of classical PDB in adults. The guideline focused
on classical PDB and did not consider the diagnosis or
management of rare PDB-like syndromes.
We evaluated tools for the diagnosis of PDB and evaluation
of disease extent, the effects of bisphosphonates and other
drug treatments on various clinical outcomes, the predictors
of treatment response, and the effects of nonpharmacolog-
ical treatments. Because of limitations in the evidence base,
we were unable to evaluate how well imaging techniques
and biochemical tests performed in differentiating PDB from
other conditions such as hyperostosis frontalis interna,
chronic nonbacterial osteomyelitis, and osteosclerotic me-
tastases or in evaluating the clinical role and performance of
invasive techniques like bone biopsy in differential diagnosis.
That being said, clinical experience indicates that PDB can
usually be differentiated quite easily from other conditions
by the patient’s clinical characteristics and the typical
appearances of the disease on radiographic and scintigraphic
examination.(61)
The guideline will be of interest to rheumatologists,
endocrinologists, physicians involved in care of older people,
orthopedic surgeons, internal medicine specialists, metabolic
medicine specialists, radiologists, general practitioners, special-
ist nurses, clinical biochemists, rehabilitation specialists, phys-
iotherapists, occupational therapists, and pharmacists who are
involved in the care of patients with PDB. Patients affected by
PDB, their caregivers, and other family members may also ﬁnd
the guideline to be of interest.
It should be noted that adherence to the recommendations
may not ensure a successful outcome in every case, nor should
they be construed as including all proper methods of care or
excluding other acceptable methods of care aimed at achieving
the same result. The ultimate judgement must be made by the
appropriate health care professional(s) responsible for clinical
decisions regarding a particular clinical procedure or treatment
plan. This judgement should only be arrived at after discussion
of the options with the patient, covering the diagnostic and
treatment choices available. It is advised, however, that
signiﬁcant departures from guidelines should be fully docu-
mented in the patient’s medical records at the time the relevant
decision is taken.
Recommendations within this guideline are based on the
best available clinical evidence. Some recommendations may
include the prescription ofmedicines for which they do not have
marketing authorization (a product license). Medicines may be
prescribed outside their product license in some countries, and
this can be necessary for a variety of reasons such as if the clinical
need cannot be met by licensed medicines. In such cases, off-
label prescribing may be employed, provided it is supported by
clinical evidence and experience.
Methods
The Guideline Development Group (GDG) was established in
January 2016 by the UK Paget’s Association, the European
Calciﬁed Tissues Society, and the International Osteoporosis
Foundation, which incorporated a multidisciplinary panel of
medical practitioners with experience in rheumatology, endo-
crinology, internal medicine, clinical biochemistry, a nonclinical
scientist, a specialist nurse, and one lay member (a patient with
PDB). All members were volunteers and none received payment
for their participation.
The GDG identiﬁed six relevant key questions (KQ) (Supple-
mental Appendix S1) and used the 2013 update of GRADE
methodology (https://gdt.gradepro.org/app/handbook/
handbook.html) to assess the strength of evidence and to
formulate recommendations.(62–65)
A literature search based on each of the KQ was performed
according to GRADE recommendations. Search strategies and
ﬂow diagrams for each search are provided in Supplemental
Appendix S2. The initial search was performed in August 2016
supervised by Dr Ruth Wills from the medical communications
company International Medical Press (www.intmedpress.com).
We incorporated search ﬁndings from the 2017 Cochrane
review,(66) which focused on bisphosphonate treatment of PDB
in March 2017. The search was updated in January 2018 but no
new articles of relevance to the KQ were identiﬁed. We initially
searched for systematic reviews that addressed the KQ followed
by randomized controlled trials if no systematic reviews
were available. If no randomized controlled trials had been
performed, we searched for observational studies and case
series, provided the number of individuals studied was greater
than 10. Individual case reports and case series of fewer than 10
subjectswere generally excluded, unless these provided insights
into the questions that were not addressed by larger studies or
clinical trials. The summary of ﬁndings in these articleswere used
to grade the quality of evidence. For other interventions and
diagnostic tests, the panel conducted their own review by
assessing the articles that were relevant to the question and
excluding articles that were not. Signiﬁcant limitations were
found when dealing with diagnostic tests for PDB because most
studies were performed in patients known to have PDB. Because
of this, there were very few reliable studies that could be used to
establish the accuracy of different diagnostic tests. The GDG
noted that PDB does not have a single gold standard test for
diagnosis, since both X-rays and radionuclide bone scans can
provide different information that often can be considered
diagnostic of PDB.
Themembers of the GDG assessed the quality of the evidence
according to the methodology described by the GRADE system.
In this system, quality of supporting evidence is assessed based
on explicit methodological criteria and classiﬁed as “high”
(further research is very unlikely to change our conﬁdence in the
estimate of effect), “moderate” (further research is likely to have
an important impact on our conﬁdence in the estimate of effect
and may change the estimate), “low” (further research is very
likely to have an important impact on our conﬁdence in the
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estimate of effect and is likely to change the estimate), or “very
low” (any estimate of effect is very uncertain).
The method we used for wording of recommendations is
shown in Table 1. The GDG considered the quality of evidence,
the balance between beneﬁt and harms, patients’ values and
preferences, and the resources and potential costs involved. For
instances where interventions or investigations were recom-
mended (or not recommended), the GDG felt that the beneﬁts
clearly outweighed the harms for most people or vice versa. For
instances where there was a closer balance between beneﬁts
and harm for interventions and investigations, the GDG made a
conditional recommendation. For conditional recommenda-
tions, the GDG felt that clinicians should discuss with patients
and families the relative merits of alternative management
options to the intervention to help each patient arrive at a
decision consistent with his or her values and preferences.
For instances where there was insufﬁcient evidence to support
theuse of an interventionor investigation for a speciﬁc indication,
it was agreed that a statement should be made to acknowledge
that the intervention or investigation was not recommended.
The guideline process was validated in accordance with the
Appraisal of Guidelines for Research and Evaluation, using the
AGREE reporting checklist 2016.(67)
The draft guidelines were sent to several stakeholders and
were externally reviewed by the representatives from the
American Society of Bone and Mineral Research, the European
Calciﬁed Tissues Society, the International Osteoporosis Foun-
dation, the British Geriatrics Society, the Bone Research Society
(UK), as well as several patients who are members of the UK
Paget’s Association. Several other organizations were invited to
comment but did not respond (Supplemental Appendix S3). The
ﬁnal version of the guideline was revised and updated to take
account of the comments that were received. The GDG intends
to conduct regular reviews every 3 years after publication of the
guidance to determine whether the evidence base has
progressed signiﬁcantly enough to alter the current guideline
recommendations and require an update.
Results and Recommendations
In this section, the results of the literature search are
summarized, along with the recommendations of the guideline
group for each key question that was posed.
Diagnosis of Paget’s disease of bone
The following section deals with techniques used for the
diagnosis of PDB. A limitation of the studies described in this
section is that with one exception(68) the literature search failed
to identify any studies inwhich diagnostic tools were assessed or
compared in a population-based setting. Similarly, no studies
were identiﬁed that addressed the order in which diagnostic
tests should be used. In view of this, the present section reports
upon the performance of different modalities in evaluating the
presence and extent of the disease in patients suspected to
have PDB.
Radiographs
The radiological features of PDB have been reviewed else-
where.(69) The disease has characteristic features on X-ray that
are summarized in Table 2 and illustrated in Fig. 1. Individually,
these features are not speciﬁc, but when they occur in
combination, they are usually diagnostic.
Gua~nabens and colleagues(70) investigated the issue of how
many regions of the skeleton would need to be X-rayed to pick
up PDB, based on analysis of plain X-rays and radionuclide
bone scans in 208 patients already known to have PDB from a
disease registry in Spain. The study showed that compared with
bone scan, an abdominal X-ray (deﬁned as an X-ray that includes
the lower ribs and femoral heads) would pick up PDB in 79% of
cases; that addition of an X-ray or the skull and facial bones
would increase the pickup rate to 89%; and that addition of an
X-ray of the upper tibias increased the pickup rate to 93%. The
evidence summary and recommendations for the use of X-rays
in the diagnosis and assessment of patients with PDB are shown
in Table 3.
Table 1. Wording of Recommendations
Recommendation Language Meaning for patients Meaning for clinicians
Positive
recommendation
The intervention or
investigation is
recommended.
Most patients would want the
intervention or investigation.
Most patients should receive the
intervention or investigation.
Negative
recommendation
The intervention or
investigation is not
recommended.
Most patients would not want
the intervention or
investigation.
Most patients should not receive the
intervention or investigation.
Conditional
recommendation
The intervention or
investigation may be
considered.
Some patients would want the
recommended intervention or
investigation but others
would not.
Different choices may be applicable to
different patients depending on their
values and preferences. The clinician
should discuss the risks and benefits with
the patient before reaching a decision.
Insufficient evidence The intervention or
investigation is not
recommended.
Most patients would not want
the intervention or
investigation.
Most patients should not receive the
intervention or investigation.
Table 2. X-ray Features of PDB
Osteolytic areas
Cortical thickening
Loss of distinction between cortex and medulla
Trabecular thickening
Osteosclerosis
Bone expansion
Bone deformity
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Radionuclide bone scintigraphy
Radionuclide bone scintigraphy is widely considered to be a
valuable technique for the diagnosis of PDB and assessment of
disease extent.(71) Radionuclide bone scanning is performed
after intravenous injection of the gamma-emitting isotope
Technetium-99m (Tc99m) linked to a bisphosphonate (most
commonly as Tc99m-methylene diphosphonate). When PDB
involves a bone, the radiolabeled bisphosphonate accumulates
in sites where there is high bone remodeling. In PDB, sites of
involvement are visualized as a region of intense and
homogeneous tracer uptake, which in long bones starts at
the metaphysis and extends down the shaft. Although many
other conditions such as ﬁbrous dysplasia, infections, metasta-
ses, and arthritis can be associated with increased tracer uptake
on bone scans, the appearances in PDB usually allow
differentiation from other conditions. In certain sites, the
scintigraphic features of PDB are highly speciﬁc. These are
“clover” or “mickey mouse sign” and the “heart sign” when PDB
affects the spine.(72,73) This observation can be of value in the
differential diagnosis with vertebral metastases but false-
positive results have been described.(74) Several investigators
have compared the performance of bone scanning with plain
X-rays in the evaluation of PDB. Wellman and colleagues
compared the performance of radionuclide bone scans with
X-rays in 108 PDB patients.(75) They reported that 101 lesions
were detected both by X-rays and radionuclide scans; that a
further 36 lesions were detected only on radionuclide scan and
not by X-ray; and that 11 lesions were detected by X-ray only.(75)
They concluded that radionuclide bone scan was more sensitive
than X-ray in detecting sites of involvement but that scan may
be negative in sclerotic (“burned out’) lesions. Another study by
Meunier and colleagues(76) compared the performance of X-rays
and radionuclide scans in 170 PDB patients. They reported
evidence of increased tracer uptake in 863 sites of which 16
(1.9%) showed changes consistent with osteoarthritis; 6 (0.7%)
with changes consistent with bone metastases, and 3 (0.35%)
with changes consistent with vertebral fractures. Of the 838 sites
showing scintigraphic changes consistent with PDB, 727 (86.7%)
showed evidence of PDB on X-ray. Seventy-one (8.4%) showed
Fig. 1. X-ray features of PDB. Pelvic radiograph from a patient with PDB affecting the upper right femur showing alternating areas of osteolysis and
osteosclerosis in the greater and lesser trochanters and femoral neck; loss of distinction between the cortex and medulla in the upper femur; bone
expansion and deformity of the affected femur; and a pseudofracture on the lateral aspect of the femur opposite the lesser trochanter.
Table 3. Role of X-rays in the Diagnosis of PDB
Risk-benefit balance
Plain X-rays targeted to the abdomen, skull, and facial bones
and both tibias are likely to detect 93% of PDB bone lesions
compared with 79% for an abdominal X-ray. The benefit to
the patient in making a diagnosis from having additional
radiographs is likely to outweigh the risk to the patient in
terms of the additional radiation exposure.
Quality of evidence
Very low
Patient values and preferences
It’s likely that the majority of patients would be content with
having radiographs of three sites as opposed to one to more
accurately make a diagnosis of PDB.
Costs and use of resources
Plain X-rays are widely available and relatively inexpensive.
Recommendation
Plain X-rays of the abdomen, tibias, skull, and facial bones are
recommended as an initial diagnostic screening test in
patients suspected to have PDB on biochemical or clinical
grounds.
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changes typical of PDB on bone scan only, and in another 23
sites, radiographs were positive and bone scans were negative.
The authors reported that of 863 sites detected on bone scan,
30.6% were symptomatic. The authors concluded that bone
scans are more sensitive than radiographs at detecting PDB
lesions but that bone scans may be negative if the disease is
inactive. A further comparative study of 23 patients with PDB
showed 127 sites of involvement of which 120 (94.5%) were
recognized on scan compared with 94 (74%) on radiological
skeletal survey.(77) Of these, 7 lesions (5.5%) were detected on
X-ray only and 33 (25.9%) on bone scan only; lesions were
detected by both modalities in 87 (67.5%) sites. When data from
these three studies are combined, 83.5% of bone lesions in PDB
were detected by both X-rays and radionuclide bone scans;
12.8% by bone scan only, and 3.7% by X-ray only. The evidence
summary and recommendations for the use of radionuclide
bone scans in the diagnosis and assessment of patients with PDB
are shown in Table 4.
Magnetic resonance imaging and computed
tomography
There have been few studies on the role of magnetic resonance
imaging (MRI) and computed tomography (CT) in the diagnosis
of PDB. Roberts and colleagues compared the appearances of
MRI, CT, and plain radiographs in 13 patients with PDB.(78) The
MRI ﬁndings and CT ﬁndings were consistent with the
abnormalities found in plain radiographs. Another study
compared CT appearances of the skull in 10 patients with
PDB with those in 10 patients with ﬁbrous dysplasia (FD) of the
skull.(79) The authors identiﬁed 10 differentiating features
including a ground glass appearance (favoring FD), symmetric
cranial involvement (PDB), thick cortices (PDB) and involvement
of the sinuses, sphenoid, orbit, and nasal cavity (all favoring FD).
Although the use of MR imaging and CT imaging is not
generally indicated for the diagnosis of PDB, clinical experience
indicates that MRI and/or CT imaging is very useful for the
investigation of several complications of PDB, including basilar
invagination, spinal stenosis, and osteosarcoma.(78) The evi-
dence summary and recommendations for the use of MRI scans
and CT scans in the diagnosis and assessment of patients with
PDB are shown in Table 5.
Biochemical markers
The elevations in bone remodeling that are characteristic of
active PBD can be detected clinically by measurement of
biochemical markers of bone turnover in blood and urine
samples. It should be noted, however, that elevations in markers
of bone turnover occur in many disease states and cannot be
used in isolation for the diagnosis of PDB.
Themost widely used biochemical marker for the diagnosis of
PDB is serum total alkaline phosphatase (ALP), which is usually
performed as part of liver function tests in a routine
biochemistry screen. A population-based study by Eekhof(68)
speciﬁcally looked at the performance of ALP in detecting PDB in
participants of the Rotterdam study in Holland. The researchers
selected 105 individuals from a cohort of 4406 subjects who had
an elevated total ALP with normal transaminases and matched
these subjects with 625 controls who had a normal total ALP.
They found that the relative risk for PDB (based on radiographs
of the hands, spine, pelvis, and knees) in the presence of a raised
total ALP was 10.9 (95% CI 4.8–24.9) in men and women older
than 55 years of age.(68) This is the only study that has addressed
the accuracy of any biochemical marker for the diagnosis of PDB.
It showed that the sensitivity of total ALP was 57.7% (95% CI
38.9–74.5); speciﬁcity 88.9% (95% CI 85.9–91.3); positive
likelihood ratio 5.19 (95% CI 3.45–7.82); and negative likelihood
ratio 0.48 (95% CI 0.30–0.75). It should be noted that the
calculated sensitivity may be an underestimate because
radiographic assessment of PDB in the study didn’t include
the skull and some patients with PDB of this site could have been
missed. It’s also important to emphasize that of 26 patients with
radiological features of PDB, only 11 (42%) had elevated total
ALP concentrations.
The performance of various biochemical markers of bone
turnover in patients with PDB was studied by Alvarez in 51
patients who had not received treatment in the previousTable 4. Role of Radionuclide Bone Scans in the Diagnosis of
PDB
Risk-benefit balance
Radionuclide bone scans are more sensitive than radiographs
at detecting bone lesions in PDB, but radiographic evidence
of PDB may be observed in about 3.7% of sites when the
bone scan is negative. However, the majority of sites
detected by imaging are asymptomatic.
Quality of evidence
Very low
Patient values and preferences
It is likely that many patients may not object to having a bone
scan in addition to targeted radiographs to fully assess the
extent of PDB.
Costs and use of resources
Radionuclide bone scans are widely available but are more
expensive than plain X-rays.
Recommendation
Radionuclide bone scans, in addition to targeted radiographs,
are recommended as a means of fully and accurately
defining the extent of the metabolically active disease in
patients with PDB.
Table 5. Role of MRI and CT Scanning in the Diagnosis of PDB
Risk-benefit balance
The radiation exposure with CT scans is higher than plain X-
rays or radionuclide bone scans, but MRI scans do not
involve radiation exposure.
Quality of evidence
Very low
Patient values and preferences
Patients with claustrophobia may prefer to avoid MRI.
Costs and use of resources
Both CT scans and MRI scans are considerably more expensive
than plain X-rays or radionuclide bone scans.
Recommendation
There was insufficient evidence to recommend MRI or CT
imaging for the diagnosis of PDB and neither technique is
recommended for this purpose. These imaging techniques
are recommended for the assessment of disease
complications.
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6 months. This showed that of the markers studied, procollagen
type I N-terminal propeptide (PINP) showed the highest
proportion of increased values among bone formation markers
when compared with BALP and total ALP (94%, 82%, and 76%,
respectively).(80) In the same study, urinary cross-linked N-
terminal telopeptide of type I collagen (uNTX) values were
increased in 96% of patients with PDB compared with urinary
pyridinoline (uPYD) (69%), urinary deoxypyridinoline (uDPD)
(71%), and urinary cross-linked beta C-terminal telopeptide of
type I collagen (ubCTX) (65%). Osteocalcin (OC) was increased in
only 34% of patients. Another study by the same group of
researchers(81) evaluated total ALP and bone alkaline phospha-
tase (BALP) in a series of 59 patients with PDB who had been
untreated for at least 6months, alongwith various othermarkers
including the carboxy-terminal propeptide of type I collagen
(PICP), tartrate-resistant acid phosphatase (TRAP), telopeptide
carboxyterminal propeptide of type I collagen (ICTP), urinary
pyridinoline (PYD), and deoxypyridinoline D-PYR) and hydroxy-
proline (HYP). Total ALP values were elevated in 74.5% of
patients, but BALP was elevated in 90%. The best-performing
resorptionmarker was D-PYD, whichwas elevated in 73%. Of the
15 subjects with normal total ALP, serum BALP was increased
in 60%.
Woitge and colleagues reported that uNTX values were
increased in 94% of a small series of 18 PDB patients compared
with 64% for serum cross-linked beta C-terminal telopeptide of
type I collagen (sbCTX).(82) In the same study, total ALP was
increased in 100% of cases.(82)
The role of biochemical markers in predicting disease extent
was evaluated in a systematic review by Al-Nofal and
colleagues.(83) This study synthesized data from17 observational
studies and 1 randomized trial in patients with PDB. Themarkers
included were serum total ALP, BSALP, uNTX, ubCTX, sbCTX,
and PINP. In treatment-na€ıve patients, circulating concentra-
tions of all markers were found to be highly signiﬁcantly
associated with extent of PDB as determined by radionuclide
bone scintigraphy. The correlation between marker concen-
trations and disease extent for individual markers were BSALP
¼ 0.750 (95% CI 0.621–0.839); PINP¼ 0.756 (95% CI 0.692–
0.809); total ALP¼ 0.617 (95% CI 0.518–0.700), sbCTX¼ 0.583
(95% CI 0.324–0.761); ubCTX¼ 0.589 (95% CI 0.332–0.765); and
uNTX¼ 0.796 (95% CI 0.702–0.862). The p value for differences
between the individual markers was not signiﬁcant (p¼ 0.083).
The evidence summary and recommendations for the use of
biochemicalmarkers in the diagnosis and assessment of patients
with PDB are shown in Table 6.
Effects of drug treatment in Paget’s disease
This section focuses on drug treatment for PDB and the effects
of treatment on complications and clinical features of the
disease. Two broad categories of drug treatment are commonly
used in patients with PDB. Speciﬁc anti-Pagetic treatment
involves the use osteoclast inhibitors to reduce the elevations
in bone turnover that are characteristic of active disease,
whereas other treatments such as analgesics, nonsteroidal anti-
inﬂammatory drugs, and anti-neuropathic agents are used for
symptom control.(54,84) We have mainly focused on the use of
bisphosphonates, which are currently considered to be the
treatment of choice for PDB and which are the only agents that
have been evaluated in randomized controlled trials.(66)
Through the literature review, we identiﬁed studies of several
osteoclast inhibitors that had been employed at some point in
the treatment of PDB, including glucagon,(85) mithramycin,(86)
actinomycin D,(87) and gallium nitrate.(88) These were not
considered further because the guideline group felt they were
of historical interest and were evaluated in uncontrolled studies
with no comparator. Similarly, supportive treatments such as
nonsteroidal anti-inﬂammatory drugs, anti-neuropathic agents,
and analgesics are widely used for pain control in patients with
PDB, and in the PRISM study, at least one of these agents was
used by all patients.(54) We did not identify any trials in which the
effectiveness of these agents was investigated speciﬁcally in
PDB. The effects of denosumab(89) and calcitonin(90) in PDB were
also reviewed and are discussed separately within this article.
Bone pain
Bone pain in PDB is a complex symptom that is associated with
increased bone turnover but that may also occur in patients
without increasedmetabolic activity. This section focuses on the
effects of bisphosphonates in the treatment of bone pain.
Although other drugs such as analgesics, nonsteroidal anti-
inﬂammatory drugs, and anti-neuropathic agents are often used
in the management of bone pain associated with PDB, these
agents haven’t been investigated in controlled clinical trials.
Calcitonin and denosumab have also been reported to improve
bone pain in PDB but are discussed separately because neither
has been investigated in randomized trials.
A meta-analysis of placebo-controlled studies with various
bisphosphonates(66) involving a total of 418 subjects showed
that these drugs were effective at reducing bone pain compared
with placebo such that the proportion of patients who achieved
any reduction in bone pain was 45% versus 23% (relative risk
[RR]¼ 1.97, 95%CI 1.29–3.01; number needed to treat [NNT]¼ 5,
95%CI 2–15). It should be noted that all but one of these trials(53)
involved etidronate(91–93) or tiludronate,(94–96) which are no
longer in widespread use.
A randomized open-label trial involving 89 subjects(97)
showed that a single intravenous infusion of 4mg zoledronic
Table 6. Role of Biochemical Markers in the Diagnosis of PDB
Risk-benefit balance
The risk of having to provide blood or urine samples for
diagnosis is minimal and outweighed by the benefit of
making a correct diagnosis.
Quality of evidence
Very low
Patient values and preferences
Most patients are unlikely to be concerned about providing a
blood or urine sample.
Costs and use of resources
Serum total ALP is widely available and considerably cheaper
than other biochemical markers that have been assessed in
PDB.
Recommendation
Serum total ALP is recommended as a first-line biochemical
screening test in combination with liver function tests in
screening for the presence of PDB. If total ALP values
are normal and clinical suspicion of metabolically active
PDB is high, measurement of BALP, PINP, or uNTX may
be considered to screen for metabolically active
disease.
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acid was more likely to give pain relief than 30mg intravenous
pamidronate when given on 2 consecutive days every 3 months
(RR¼ 1.30, 95% CI 1.10–1.53; NNT¼ 5, 95% CI 3–11). A
randomized open-label trial comparing intravenous pamidro-
nate 60mg intravenously every 3 months with oral alendronic
acid 40mg daily in 3-month blocks reported no difference in
bone pain between the treatments, although the article did not
include detailed information on this outcome.(98) Another
randomized double-blind study involving 357 patients pub-
lished by Reid and colleagues(99) showed that zoledronic acid
given as a single dose of 5mg intravenously was more likely to
give pain relief than risedronate sodium 30mg daily orally for
2 months (RR¼ 1.36, 95% CI 1.06–1.74; NNT¼ 7, 95% CI 4–24).
An insight into the durability of the response of pain with
different bisphosphonates comes from an extension of the Reid
study,(100) which compared the effects of a single dose of
zoledronic acid 5mgwith a single 2-month course of risedronate
sodium 30mg daily. The extension study focused on a subgroup
of 267 individuals in whom total ALP values were normal at the
end of the core study. Clinical relapse, as deﬁned by recurrence
of bone pain, occurred in 14 of 152 (9.2%) patients in the
zoledronic acid group compared with 29 of 115 (25.2%) in the
risedronate sodium group. It should be noted that the rate of
clinical relapse was more than 10 times greater than the rate of
biochemical relapse in the zoledronic acid group (0.7%) and was
about 25% greater than the rate of biochemical relapse in the
risedronate sodium group (20%). This indicates that biochemical
relapse of PDB and clinical relapse as deﬁned by the recurrence
of pain are distinct entities.
The evidence summary and recommendations for the use of
bisphosphonates to treat bone pain in PDB are shown in
Table 7.
Health-related quality of life
No information was available from randomized trials with which
to evaluate the effects of bisphosphonates on health-related
quality of life compared with placebo.
A comparison of zoledronic acid with risedronate sodium(99)
showed that the average physical component summary score of
SF-36 improved to a greater extent in the zoledronic acid group,
although the absolute difference was about 2 points, which is
below the 5-point threshold that is considered clinically
signiﬁcant.(99) When the SF36 physical summary score data
were analyzed bymultivariate testing taking baseline scores into
account, the authors reported a nominally signiﬁcant difference
(p¼ 0.04) favoring zoledronic acid, but this was not adjusted for
multiple comparisons. When the data were expressed as the
proportion of patients whose SF36 physical summary score
improved after treatment, the difference favored zoledronic acid
(RR¼ 1.30, 95% CI 1.18–1.42).(66) In an extension of the same
study,(100) the mean change from baseline SF36 summary score
favored zoledronic acid (mean difference 3.8, 95% CI 3.12–4.49).
However, this analysis was not intention to treat, and was based
on a selected group of patients who had normal total ALP values
at the end of the core study.
The evidence summary and recommendations for the use of
bisphosphonates to improve quality of life in PDB are shown in
Table 8.
Prevention of fractures
Fractures in patients with PDB can be divided into two
categories: those that occur in affected bone (pathological
fractures) and those that occur in unaffected bone. The vast
majority of pathological fractures in PDB affect the femur or
tibia. The literature review revealed that there was insufﬁcient
evidence to evaluate the effects of bisphosphonates on incident
Table 7. Effect of Bisphosphonate Treatment on Bone Pain
Risk-benefit balance
Bisphosphonates improve bone pain in PDB compared with
placebo and comparative studies within bisphosphonates
have shown that zoledronic acid is more likely to give an
improvement than pamidronate and risedronate sodium.
These bisphosphonates have a generally favourable adverse
effect profile. In addition, most patients required other pain-
relieving medications such as analgesics and nonsteroidal
anti-inflammatory drugs for pain control.
Quality of evidence
Moderate
Patient values and preferences
Most patients that have bone pain are likely to favor the
potential benefits of bisphosphonates with or without other
analgesics considering their generally favorable adverse
event profile.
Costs and use of resources
Bisphosphonates are inexpensive, but intravenous therapy
involves additional support costs and costs in terms of
patient time attending for the infusion that need to be
considered.
Recommendation
Bisphosphonates are recommended for the treatment of bone
pain associated with Paget’s disease. Zoledronic acid is
recommended as the bisphosphonate most likely to give a
favorable pain response.
Table 8. Effect of Bisphosphonate Treatment on Health-Related
Quality of Life
Risk-benefit balance
We found no evidence to evaluate the effects of
bisphosphonates on quality of life compared with placebo.
We found evidence that zoledronic acid improved some
aspects of quality of life more than risedronate sodium, but
the differences were below the threshold that is considered
clinically significant.
Quality of evidence
Very low
Patient values and preferences
Quality of life is important to patients. If treatment strategies
could be identified that offered a significant improvement in
quality of life, it is likely that they would be favored by
patients.
Costs and use of resources
Bisphosphonates are inexpensive, but intravenous therapy
involves additional support costs and costs in terms of
patient time attending for the infusion that need to be
considered.
Recommendation
There is insufficient evidence that bisphosphonate therapy
improves quality of life to a clinically meaningful extent in
PDB, and they are not recommended for this indication.
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fractures of either category when compared with placebo. A
Cochrane review(66) of placebo-controlled trials reported that
information on fracture was only available in 356 participants,
and the reports did not distinguish pathological fractures from
fractures in unaffected bone. In these studies, the rate of
fractures in the placebo group was 0 of 79 (0%) versus 4 of
277 (1.4%) in the bisphosphonate group (RR¼ 0.89, 95% CI
0.18–4.31). There was no data onwhich to evaluate the effects of
different individual bisphosphonates on incident fractures or to
evaluate the effects of bisphosphonates on fractures in bone
affected by PDB.
The evidence summary and recommendations for the use of
bisphosphonates to prevent fractures in PDB are shown in
Table 9.
Progression of osteoarthritis
There was no evidence upon which to evaluate the effects of
bisphosphonates on progression of osteoarthritis compared
with placebo, and no evidence to evaluate the effects of
individual bisphosphonates compared with one another on
progression of osteoarthritis.
The evidence summary and recommendations for the use of
bisphosphonates to prevent progression of osteoarthritis in PDB
are shown in Table 10.
Progression of hearing loss
The effects of treatment on hearing loss is considered separately
from neurological symptoms for two reasons: the ﬁrst is that it
has been studied separately and the second is that inmany cases
deafness is not due to nerve compression but is a conductive
deafness possibly related to abnormalities in the temporal
bone.(101) There was no evidence from randomized trials upon
which to evaluate the effects of bisphosphonates compared
with placebo; no evidence to compare the effects of individual
bisphosphonates; and no evidence to compare the effects of
other treatments with bisphosphonates or other treatments
with placebo. We identiﬁed one observational study of 25 PDB
patients(102) in which the effects of tiludronate (400mg daily for
3 months; n¼ 15) or pamidronate (30mg i.v. for 6 days; n¼ 10)
on hearing loss were studied in patients with PDB of the
skull. Audiometry demonstrated sensorineural hearing loss
in 12 patients, conductive hearing loss in 4, and a mixed pattern
in 6 patients. The authors reported no signiﬁcant change in
hearing thresholds after 12 months overall, although they
commented that there was a nonsigniﬁcant (7.5 db) increase in
hearing thresholds in the high-frequency region in those with
sensorineural loss.(102)
The evidence summary and recommendations for the use of
bisphosphonates to prevent progression of hearing loss in PDB
are shown in Table 11.
Table 9. Effect of Bisphosphonate Treatment on Fracture
Prevention
Risk-benefit balance
The effects of bisphosphonates on prevention of fractures in
PDB have not been adequately studied.
Quality of evidence
Very low
Patient values and preferences
Prevention of fractures is valued by patients with PDB. If
treatment strategies could be identified that were effective
in preventing fractures, it is likely that they would be favored
by patients.
Costs and use of resources
Bisphosphonates are inexpensive, but intravenous therapy
involves additional support costs and costs in terms of
patient time attending for the infusion that need to be
considered.
Recommendation
There is insufficient evidence that bisphosphonate therapy
prevents fractures in PDB, and they are not recommended
for this indication.
Table 10. Effect of Bisphosphonate Treatment on Progression of
Osteoarthritis
Risk-benefit balance
The effects of bisphosphonates on progression of osteoarthritis
have not been adequately studied.
Quality of evidence
Very low
Patient values and preferences
Prevention of osteoarthritis is likely to be valued by patients
with PDB. If treatment strategies could be identified that
were effective in preventing progression of osteoarthritis, it
is likely that they would be favored by patients.
Costs and use of resources
Bisphosphonates are inexpensive, but intravenous therapy
involves additional support costs and costs in terms of
patient time attending for the infusion that may need to be
considered.
Recommendation
There is insufficient evidence that bisphosphonate therapy
prevents progression of osteoarthritis in PDB, and they are
not recommended for this indication.
Table 11. Effect of Bisphosphonate Treatment on Progression of
Hearing Loss
Risk-benefit balance
The effects of bisphosphonates on progression of hearing loss
have not been adequately studied.
Quality of evidence
Very low
Patient values and preferences
Prevention of progression of hearing loss is likely to be valued
by patients with PDB. If treatment strategies could be
identified that were effective in preventing progression of
hearing loss, it is likely that they would be favored by
patients.
Costs and use of resources
Bisphosphonates are inexpensive, but intravenous therapy
involves additional support costs and costs in terms of
patient time attending for the infusion that may need to be
considered.
Recommendation
There is insufficient evidence that bisphosphonate therapy
prevents progression of hearing loss in PDB, and they are not
recommended for this indication.
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Blood loss during elective orthopedic surgery
There was no evidence from randomized trials upon which to
evaluate the effects of bisphosphonates compared with
placebo, the effects of individual bisphosphonates, or the
effects of other treatments on operative blood loss during
elective surgery. Some information was available from observa-
tional studies on the relation between having received anti-
Pagetic treatment and operative blood loss. Wegrzyn reviewed
the outcome of 39 cementless hip replacements in a series of
32 patients undergoing surgery in a French center between
1992 and 2006.(103) All patients received intravenous pamidr-
onate before surgery and 31 of 39 (79%) hip replacements had
been performed in patients with a normal total ALP at the time
of surgery. The average blood loss was 744mL (range
250–2000mL), which the authors commented was greater
than in patients undergoing similar procedures that did not
have PDB (range 200–450mL). Gabel(104) studied blood loss in 13
patients who had 16 total knee replacements (TKR) at a single US
center between 1974 and 1986. The average blood loss was
481mL (range 100–2000) and the authors commented that
there was no difference between blood loss in patients who had
previous treatment with either calcitonin or etidronate or those
who did not have treatment. Similar ﬁndings were reported by
Lee in 21 TKR from 20 patients referred to a US center between
1978 and 1999.(105) Blood loss was estimated as 300mL (range
100–600mL), but the authors found no difference between
blood loss in patients who had or had not received preoperative
treatment with etidronate (278mL versus 315mL, p¼ 0.32).(105)
A systematic review conducted by Jorge-Mora and colleagues
reviewed the effects of anti-Pagetic therapy on blood loss and
other outcomes after elective spinal surgery in 17 case
reports.(106) The most common indications for surgery were
spinal cord compression (n¼ 8), spinal stenosis (n¼ 6), and back
pain (n¼ 3). Bisphosphonate was given before the surgery in
7 patients, but the type of bisphosphonate used and the dose
were not recorded. Bleeding was noted as a complication in 0 of
7 patients given bisphosphonate and 4 of 10 patients not given
bisphosphonate (p¼ 0.22, Fisher’s exact test). Parvizi and
colleagues reported upon the inﬂuence of treatment on blood
loss during osteotomy in 22 PDB patients.(107) Calcitonin was
given to 6 patients and pamidronate to 3 patients before
surgery. The authors commented that excessive bleeding was
observed in all cases but did not deﬁne what was meant by
excessive bleeding. They also commented that medical
treatment signiﬁcantly reduced intraoperative blood loss and
that estimated blood loss was higher in patients with active
disease but no data on blood loss or disease activity in these
subgroups were provided.
The evidence summary and recommendations for the use of
bisphosphonates to prevent or reduce blood loss during elective
orthopedic surgery are shown in Table 12.
Bone deformity
There was no evidence from randomized trials upon which to
evaluate the effects of bisphosphonates compared with
placebo, the effects of individual bisphosphonates, or the
effects of other treatments on the prevention or treatment of
bone deformity. One case series of 9 PDB patients with facial
deformity was identiﬁed.(108) Each of these patients was treated
with etidronate or clodronate for between 1 and 6 years, and
facial deformity was measured using a stereophotogrammetric
technique. Based on this analysis, the authors reported that
facial deformity (as reﬂected by a derived measure of facial or
skull volume) improved in 7 of 8 cases.
The evidence summary and recommendations for the use of
bisphosphonates to prevent progression of bone deformity in
PDB are shown in Table 13.
Neurological symptoms
This section concerns the effect of treatment on neurological
symptoms other than deafness, which was considered earlier.
No randomized comparative trials were identiﬁed in which the
effects of bisphosphonates or other treatments have been
evaluated in respect to neurological symptoms. We identiﬁed
Table 12. Effect of Bisphosphonate Treatment on Blood Loss
During Elective Orthopedic Surgery
Risk-benefit balance
The data on blood loss in patients who have and have not had
bisphosphonate treatment before elective orthopedic or
spinal surgery are conflicting and difficult to interpret.
Quality of evidence
Very low
Patient values and preferences
Prevention of blood loss during surgery is likely to be valued by
patients with PDB. If treatment strategies could be identified
that were effective in preventing blood loss during elective
orthopedic surgery, it is likely that they would be favored by
patients.
Costs and use of resources
Bisphosphonates are inexpensive, but intravenous therapy
involves additional support costs and costs in terms of
patient time attending for the infusion that may need to be
considered.
Recommendation
There is insufficient evidence that bisphosphonate therapy
reduces perioperative blood loss during elective orthopedic
surgery, and they are not recommended for this indication.
Table 13. Effect of Bisphosphonate Treatment on Bone
Deformity
Risk-benefit balance
The effects of bisphosphonates on bone deformity have not
been adequately studied.
Quality of evidence
Very low
Patient values and preferences
Bone deformity is of concern to patients. If treatment strategies
could be identified that were effective in preventing bone
deformity, it is likely that they would be favored by patients.
Costs and use of resources
Bisphosphonates are inexpensive, but intravenous therapy
involves additional support costs and costs in terms of
patient time attending for the infusion that may need to be
considered.
Recommendation
There is insufficient evidence that bisphosphonates can
prevent or treat bone deformity in PDB, and they are not
recommended for this indication.
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two case series of patients that addressed this issue. Chen and
colleagues described the response to treatment with salmon or
porcine calcitonin given subcutaneously in 49 PDB patients with
neurological symptoms treated between 1969 and 1973 at a
single referral center in the US.(109) The starting dose was 100 IU
by subcutaneous injection, although subsequently the dose was
reduced in some patients to 50 IU 3 timesweekly. Treatmentwas
continued for 7 to 31 months (average 23 months). The
indication for treatment in 10 patients was cranial nerve lesions
(other than lesions of the 8th cranial nerve), spinal nerve root
dysfunction in 15, spinal cord problems in 6, and miscellaneous
neurological problems in 8. The authors reported objective
improvement in 40% of patients with a cranial nerve lesion
responded to treatment, as compared with 33% with spinal
nerve problems, 50% with spinal cord symptoms, and 0% with
miscellaneous problems. In another case series from the UK,
Douglas reported the results of treatment with calcitonin,
etidronate, or clodronate in 8 patients with neurological
dysfunction due to Paget’s disease of the spine.(50) Seven of
the 8 patients were treated with calcitonin 100 IU daily and all
improved neurologically. One patient treated with clodronate
also improved. In 3 patients whose symptoms recurred despite
treatment with calcitonin, there was a response to etidronate or
clodronate. Douglas also reviewed the results of medical
treatment of spinal dysfunction from other published case
reports with calcitonin at that time(50) and identiﬁed 13
additional patients who had been treated with calcitonin for
spinal cord dysfunction whose symptoms had improved after
therapy.
The evidence summary and recommendations for the use of
calcitonin and bisphosphonates in the treatment of neurological
symptoms in PDB are shown in Table 14.
Treatment of increased metabolic activity in
asymptomatic patients
Bisphosphonates are highly efﬁcacious at reducing the eleva-
tions in bone turnover that are characteristic of active PDB. Here
we focus on the effects of treatment on serum total ALP because
it is the most commonly used biochemical marker of metabolic
activity in PDB and has served as the primary outcome measure
in clinical trials where bisphosphonates have been compared
with placebo and with other bisphosphonates. In a Cochrane
review,(66) it was noted that bisphosphonates achieved a
50.1% (95% CI 32.5–67.7) greater reduction in total ALP (592
participants) than placebo and the RR of bisphosphonates
normalizing total ALP was 9.96 (95% CI 3.74–26.58). In the same
review, a comparison of nitrogen-containing bisphosphonates
with non-nitrogen-containing bisphosphonates showed that
nitrogen-containing bisphosphonates were more effective at
normalizing total ALP than non-nitrogen-containing bisphosph-
onates (212 participants) (RR¼ 4.3, 95% CI 2.72–6.79; NNT¼ 2,
95% CI 1–4). Within the nitrogen-containing bisphosphonates,
zoledronic acid was more efﬁcacious at reducing total ALP
than pamidronate (90 participants) or risedronate sodium
(347 participants) (RR¼ 2.57, 95% CI 1.79–3.70; NNT¼ 2, 95%
CI 1–3 and RR¼ 1.53, 95% CI 1.33–1.76; NNT¼ 3; 95% CI 3–5,
respectively.
The duration of effect of different bisphosphonates on serum
total ALP concentrations has also been studied. A randomized
trial comparing oral risedronate sodium30mgdaily for 2months
with oral etidronate 400mg daily for 6months showed that total
ALP values remained suppressed in 53% of the risedronate
sodium group compared with 14% of the etidronate group.(110)
In a long-term extension of the HORIZON Paget’s study,(100) 88%
of patients treated with a single dose of 5mg zoledronic acid
intravenously still had a normal serum total ALP after 5 years’
follow-up compared with 47% of patients treated with oral
risedronate sodium. It should be noted that the attrition rate in
this studywas high and that only patients with normal ALP at the
end of the core study were eligible to be enrolled into the
extension.
Although many clinical trials of bisphosphonates have
enrolled patients on the basis that serum total ALP values are
elevated (whether or not symptoms were present), we found
no clinical trials or observational studies that speciﬁcally
addressed the issue of whether treatment of asymptomatic
patients with bisphosphonates that have metabolically
active PDB was of beneﬁt in preventing complications of
the disease.
Of some relevance to the issue of treating asymptomatic
patients is the fact that bisphosphonates can promote healing of
lytic lesions at least in the short term. In one observational study
of PDB patients treated with pamidronate, healing of lytic
lesions was demonstrated in some cases at 6 months, but
longer-term follow-up of these patients after 2 years showed
progression of lytic lesions once again, even though biochemical
markers of bone turnover were normal at this point.(111) The
effects of bisphosphonates on lytic lesions have been studied in
two randomized controlled trials. One examined the effects of
alendronic acid 40mg daily for 6 months in 55 PDB patients
compared with placebo. The average age was about 70 years;
Table 14. Effect of Calcitonin and Bisphosphonates on
Neurological Symptoms
Risk-benefit balance
Most experience in the medical treatment of spinal cord
dysfunction in PDB comes from case series of patients
treated with calcitonin, and clinical benefit from treatment
has been reported in a proportion of treated patients. Similar
benefit has been noted in a small number of patients treated
with bisphosphonates.
Quality of evidence
Very low
Patient values and preferences
Spinal cord dysfunction and the symptoms associated with this
complication is of major concern to patients. Treatment
strategies that are effective in preventing spinal cord
dysfunction are likely to be favored by patients.
Costs and use of resources
Calcitonin is a relatively expensive treatment that needs to be
administered by injection. Bisphosphonates are inexpensive
but have been little studied in this situation. Intravenous
bisphosphonate therapy involves additional support costs
and costs in terms of patient time attending for the infusion
that may need to be considered.
Recommendation
A trial of calcitonin treatment may be considered as part of
the treatment package in patients with PDB who have
evidence of neurological dysfunction. Bisphosphonate
treatment may also be considered, although there are few
studies to support the use of bisphosphonates in this
situation.
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19% had previously been treated with anti-Pagetic medication
and 32 (58%) had bone pain thought to be due to PDB at
baseline. The authors reported healing of lytic lesions in 11 of 23
(47.8%) patients treated with alendronic acid and no change in
12 of 23 (52.1%) patients. Corresponding values in placebo-
treated patients were 1 in 23 healed and no change in 22 of 23
patients (95.6%). Bone biopsies were obtained through Paget’s
bone in 4 alendronic acid–treated patients and 9 placebo-
treated patents. Histomorphometry showed lower bone turn-
over in the alendronic acid–treated cases. Another randomized
trial compared the effects of alendronate 40mg daily for
6 months with etidronate 400mg daily for 6 months in 89 PDB
patients of average age about 70 years.(112) It showed that
lesions improved in 32.4% of the ALN group, whereas 8.8%
showed worsening. The corresponding proportions in the
etidronate group were 26.5% and 14.7%, respectively, a
difference that was not signiﬁcant.
The issue of giving bisphosphonates with the aim of
suppressing bone turnover in established PDB was addressed
by the PRISM trial, which is discussed in more detail later. The
GDG noted that risks and beneﬁts of giving prophylactic
zoledronic acid to asymptomatic people at risk of developing
PDB was being addressed by the ZiPP study (EUDRACT 2008-
005667-34), which is due to report in 2020.
The evidence summary and recommendations for the use of
bisphosphonates with the primary aim of supressing bone
turnover symptoms in asymptomatic patients with PDB are
shown in Table 15.
Neoplastic transformation
There was no evidence from randomized trials upon which to
evaluate the effects of bisphosphonates compared with
placebo; the effects of individual bisphosphonates; or the
effects of other treatments on the prevention of osteosarcoma
or GCT. Similarly, no observational studies were identiﬁed that
evaluated the effects of treatment on neoplastic transformation.
The evidence summary and recommendations for the use of
bisphosphonates with aim of preventing neoplastic transforma-
tion in PDB are shown in Table 16.
Adverse events
This section evaluates the adverse events that have been
reported with bisphosphonate treatment with an emphasis of
those of relevance to the treatment of PDB. Atypical femoral
fractures, uveitis, osteonecrosis of the jaw, hypocalcemia, and
impaired renal function are recognized to be rare adverse effects
of bisphosphonates. A recent Cochrane review(66) evaluated the
frequency of rare adverse events in PDB patients treated with
bisphosphonates by reviewing the websites of the Food and
Drug Administration (FDA), the Medicines and Healthcare
products Regulatory Agency (MHRA), the European Medicines
Agency (EMA), and the Australian Regulatory Agency (AARB).
The estimated frequency of osteonecrosis of the jaw (ONJ) in
people with PDB receiving oral bisphosphonates was estimated
as between 0.0004% and 0.06%, which is much lower than in
osteoporosis. There is no clear evidence regarding the risk of
ONJ after use of intravenous bisphosphonates for PDB, although
one case was reported in the PRISM-EZ study in a patient who
received intensive bisphosphonate therapy.(113) Atypical femo-
ral fractures (AFF) are thought to be a class effect of
bisphosphonates; as of 2017, the EMA had received only one
report of an AFF in a patient with PDB. The authors of the
Cochrane review speculated that the infrequent occurrence of
ONJ and AFF in PDB might be related to the fact that patients
tend to have intermittent or short-term courses for treatment of
the disease.
In a recent Cochrane review,(66) no statistically signiﬁcant
difference was found in adverse effects with oral bisphospho-
nates compared with placebo (6 studies, 678 participants, risk
Table 15. Effects of Bisphosphonate Treatment on Asymptom-
atic Patients With Increased Metabolic Activity
Risk-benefit balance
Bisphosphonates are highly effective at reducing metabolic
activity in PDB as reflected by concentrations of total ALP
and other biochemical markers of bone turnover.
Improvements in lytic lesions have also been reported in
short-term studies. The clinical benefit of giving
bisphosphonates in asymptomatic patients with the
primary aim of supressing metabolic activity is unknown.
Quality of evidence
High
Patient values and preferences
Patients with PDB who have elevated concentrations of total
ALP or other biochemical markers of bone turnover in the
absence of symptoms may or may not derive clinical benefit
from treatment. Some patients may favor treatment,
whereas others may not in view of the potential risk of
adverse effects and uncertain benefit.
Costs and use of resources
Bisphosphonates are inexpensive, but intravenous therapy
involves additional support costs and costs in terms of
patient time attending for the infusion that need to be
considered.
Recommendation
Bisphosphonate therapy may be considered to suppress
metabolic activity in PDB, but the clinical benefit is uncertain.
Within this class of drugs, nitrogen-containing
bisphosphonates are more effective than non-nitrogen-
containing bisphosphonates, and within the
bisphosphonates, zoledronic acid is most efficacious.
Table 16. Effect of Bisphosphonate Treatment on Neoplastic
Transformation
Risk-benefit balance
The effects of bisphosphonates on the prevention of neoplastic
transformation in PDB have not been adequately studied.
Quality of evidence
Very low
Patient values and preferences
Prevention of neoplastic transformation is likely to be highly
valued by patients with PDB. Treatment strategies that are
effective in preventing neoplastic transformation would
most likely be favored by patients.
Costs and use of resources
Bisphosphonates are inexpensive, but intravenous therapy
involves additional support costs that need to be considered.
Recommendation
There is insufficient evidence to show that bisphosphonates
prevent neoplastic transformation in PDB, and they are not
recommended for this indication.
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difference 0.11, 95% CI 0.00–0.22). Similarly, the risk of
discontinuation due to adverse events was similar compared
with placebo (517 participants; RR¼ 1.01, 95% CI 0.38–2.69). It
should be noted that these comparisons predominantly
involved non-nitrogen-containing oral bisphosphonates. Zole-
dronic acid was found to have an increased risk of adverse
effects when compared with placebo (RR¼ 2.57, 95% CI
1.21–5.44). The most common adverse event in studies with
zoledronic acid was a transient ﬂu-like illness.(99) The prevalence
and severity of this adverse effect has not been studied in detail
in PDB, but in osteoporosis, it was estimated to occur in 42.5% of
patients; of these episodes, 46% were considered to be mild by
the investigator, 45% moderate, and 10% severe.(114) There is
good evidence that the ﬂu-like symptoms are milder after
second and subsequent infusions of zoledronic acid compared
with the ﬁrst infusion.(114)
The evidence summary and recommendations with regard to
adverse effects of bisphosphonate treatment are shown in
Table 17.
Treatment strategy in Paget’s disease
This section focuses on randomized trials that have compared
different treatment strategies in PDB. Only three studies were
identiﬁed that directly addressed this issue. These were the
PRISM study(54) and its extension(113) and the study of
intravenous versus intramuscular neridronate.(115) All three
studies concerned the use of bisphosphonates.
Treatment of increased metabolic activity or symptoms?
The Paget’s Disease, Randomized Trial of Intensive versus
Symptomatic Management (PRISM) study compared the
effects of a treat to target strategy aimed at normalizing total
ALP compared with a strategy aimed at controlling symp-
toms(54) in 1324 patients with PDB. The average age of
participants at entry to the study was about 74 years with an
average disease duration of 8 years. About 70% of patients had
previously been treated with bisphosphonates; about 47% had
elevated total ALP values at baseline, and 46% had bone pain
thought to be caused by PDB. There was a poor correlation
between presence of bone pain thought to be due to PDB and
an elevated ALP value, however.(54) Participants randomized to
receive “intensive” bisphosphonate treatment (n¼ 661) were
prescribed bisphosphonates with the aim of maintaining or
suppressing total ALP values to within the reference range
irrespective of whether bone pain was present. Risedronate
sodium was the bisphosphonate of ﬁrst choice, but any
licensed bisphosphonate could be used. In the symptomatic
group (n¼ 663), the therapeutic goal was to control
bone pain. This was initially attempted using analgesics, but
if the response was inadequate, non-nitrogen-containing
bisphosphonates or calcitonin were used ﬁrst followed by
nitrogen-containing bisphosphonates if necessary. The primary
endpoint was clinical fracture. Secondary endpoints included
fractures through Pagetic bone, orthopedic procedures, quality
of life assessed by SF36, HAQ and EQ5D, bone pain, bone
deformity, progression of hearing loss in patients with skull
involvement assessed by audiometry, and adverse events.
PRISM was an event-driven study, which was stopped when
95 clinical fractures occurred. The average duration or follow-
up was 3 years with a range of 2 to 4 years.
The PRISM-extension with zoledronic acid study (PRISM-EZ)
employed the same strategy as in PRISM, but zoledronic acid
was used as the treatment of ﬁrst choice in the intensive arm.(113)
Patients within PRISM-EZ maintained the same treatment
allocation as they had been randomized to in PRISM. The
PRISM-EZ study followed 270 patients in the intensive group and
232 in the symptomatic group, providing an average total
duration of 7.3 years follow-up since the beginning of the PRISM
study. The primary and secondary endpoints were the same in
PRISM-EZ as in PRISM, except that patients did not undergo
audiometry in the extension.
Fractures
The number of clinical fractures in the intensive and symptom-
atic PRISM treatment arms were similar. In the intensive group,
46 of 661 (7.0%) participants had clinical fractures compared
with 49 of 663 (7.3%) in the symptomatic group (RR¼ 0.94, 95%
CI 0.64–1.39). Fractures through Pagetic bone occurred in 8 of
661 (1.2%) of the intensive group and 13 of 663 (2.0%) of the
symptomatic group (RR¼ 0.62, 95% CI 0.22–1.60). In the PRISM-
EZ trial,(113) 22 of 270 (8.1%) of participants in the intensive
group had clinical fractures compared with 12 of 232 (5.2%) in
the symptomatic group (RR¼ 1.84, 95% CI 0.76–4.44). Fractures
through Pagetic bone occurred in 5 of 270 (1.9%) in the intensive
group versus 2 of 232 (0.9%) in the symptomatic group
(RR¼ 2.15, 95% CI 0.42–10.96).
Orthopedic surgery
In the PRISM study, the number of patients undergoing
orthopedic surgery in the intensive treatment group was
48 of 661 (7.2%) and 55 of 663 (8.2%) in the symptomatic
group (RR¼ 0.88, 95% CI 0.60–1.27). Of the 103 procedures
performed, 73.7% were joint replacements for osteoarthritis. In
the PRISM-EZ study, 15 of 270 (5.5%) of patients in the intensive
group underwent orthopedic surgery compared with 7 of 232
(3.0%) patients in the symptomatic group (RR¼ 1.84, 95% CI
Table 17. Adverse Events of Bisphosphonate Treatment
Risk-benefit balance
Serious adverse events with bisphosphonates are rare. In PDB,
oral bisphosphonates have a similar adverse event profile as
placebo but that a transient flu-like illness occurs commonly
with zoledronic acid. Usually this is of mild to moderate
severity but can be severe in some patients.
Quality of evidence
Very low
Patient values and preferences
Adverse events are of concern to patients and a proportion of
individuals may decline treatment because of the risk of
adverse events.
Costs and use of resources
Bisphosphonates are inexpensive, but intravenous therapy
involves additional support costs that may need to be
considered.
Recommendation
We recommend that patients undergoing treatment with
bisphosphonates for PDB are informed about their favorable
adverse event profile. We also recommend that patients are
advised that a transient flu-like illness occurs commonly with
intravenous zoledronic acid.
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0.76–4.44). Joint replacements were also the most common
orthopedic procedure in PRISM-EZ and were more commonly
required in the intensive group 11 of 270 (4.1%) versus 4 of 232
(1.7%).
Health-related quality of life
The PRISM study showed no signiﬁcant difference in health-
related quality of life between the treatment groups at any time
point using various tools including SF36, EQ5D, and HAQ.Within
the PRISM-EZ study, small differences in some aspects of quality
of life were observed between the treatment groups at some
time points, but the differences were below the 5-point
threshold that is considered clinically signiﬁcant and were not
consistently observed at different time points.
Bone pain
The PRISM study showed no difference between treatment
groups in the proportion of patients with bone pain at 2 years
(311 of 422 [73.7%] versus 295 of 423 [69.7%], p¼ 0.20) or bone
pain thought by the clinician to be due to PDB (96 of 311 [30.8%]
versus 78 of 295 [26.4%], p¼ 0.22). In the PRISM-EZ study, there
were no differences in bone pain or bone pain thought by
the clinician to be due to PDB except at 2 years where the
standardized mean difference, calculated by propensity scoring,
showed 1.3% fewer patients with bone pain (95% CI 0.3–2.3) in
the intensive treatment group.
Progression of deafness
The PRISM study showed no signiﬁcant difference between
treatment groups in progression of hearing loss, as determined
by audiometry and the proportion of patients using a hearing
aid over an average of 3 years of follow-up. Audiometry showed
that the mean (SD) change in hearing threshold was
þ1.8 14.6 in the left ear in the intensive group compared
with 0 12.6 in the symptomatic group (mean, 95% CI
difference¼ 1.8, –3.4 to 7.0). Corresponding values in the right
ear were 2.5 5.7 versus 2.1 9.4 (mean, 95% CI difference
¼ 0.5, –2.5 to 3.3). At the baseline visit of PRISM, 151 of 663
(22.9%) of the symptomatic group and 144 of 661 (21.9%) of the
intensive group used a hearing aid. The proportion of hearing
aid users increased to a similar extent in both groups such that
by the end of study 133 of 486 (27.3%) of the symptomatic group
used a hearing aid compared with 134 of 505 (26.5%) of the
intensive group.
Adverse events
In the PRISM study, the numbers of adverse events and serious
adverse events in the two treatment groups were similar. In the
PRISM-EZ study, the number of patients with adverse events in
the intensive group was 226 of 270 (83.7%) compared with 196
of 232 (84.5%) in the symptomatic group (RR¼ 0.99, 95% CI
0.92–1.08). The number of serious adverse events in the two
treatment groups was 87 of 270 (32.2%) versus 66 of 232 (28.4%)
(RR¼ 1.28, 95% CI 0.96–1.72).
Alkaline phosphatase
In the PRISM study, serum concentrations of total ALP were
signiﬁcantly lower in the intensive group from 4 months
onward. At the end of the study, 78.8% of the intensive group
had a total ALP within the reference range compared with
61.2% of the symptomatic group (p< 0.001). In the PRISM-EZ
study, total ALP values were lower at baseline and throughout
the study in the intensive group. By the end of the study, total
ALP values were within the reference range in 85.3% of the
intensive group versus 70.3% of the symptomatic group
(p< 0.001).
The evidence summary and recommendations with regard to
employing a strategy of supressing bone turnover as the primary
therapeutic goal in PDB as opposed to treating symptoms are
shown in Table 18.
Route of administration of bisphosphonates
The literature review identiﬁed several studies in which different
modes of administration of bisphosphonates for the treatment
of PDB were investigated, but the only randomized trial was by
Merlotti and colleagues with neridronate, a nitrogen-containing
bisphosphonate licensed in Italy for PDB.(115) The study group
was composed of 57 patients with active PDB as deﬁned by a
serum total ALP value above the upper limit of the reference
range. All patients were reported to have bone pain before
treatment. Participants were randomized to receive intravenous
neridronate (100mg i.v. on 2 consecutive days) or intramuscular
neridronate (25mg once weekly for 8 weeks). The primary
endpoint was normalization of total ALP. Secondary endpoints
included bone pain and the time taken until ALP normalized.
Normalization of ALP levels at 6months was achieved in 24 of 27
patients (88.9%) in the intravenous group and 26 of 29 patients
(89.6%) in the intramuscular group. Longer-term follow-up at
36 months revealed that normal total ALP values were
maintained in 13 of 27 (48.1%) and 13 of 29 (44.8%) of patients
Table 18. Treating Symptoms or Increased Metabolic Activity
with Bisphosphonates in PDB
Risk-benefit balance
A strategy of intensive bisphosphonate therapy aimed at
maintaining total ALP concentrations within the reference
range performed similarly to a strategy of treatment with
bisphosphonates and other drugs that aimed to control
symptoms, with respect to the occurrence of clinical
fractures, fractures through Pagetic bone, requirement for
orthopedic surgery, quality of life, bone pain, and
progression of hearing loss.
Quality of evidence
Moderate
Patient values and preferences
Prevention of fractures and orthopedic procedures, and
improvements in bone pain, quality of life, and prevention of
progressive hearing loss are all highly valued by patients.
Costs and use of resources
Bisphosphonates are inexpensive drugs, but intravenous
therapy may involve additional support costs that may need
to be considered. More frequent courses of therapy increase
health care costs and resources as compared with less
frequent courses of treatment.
Recommendation
Treatment aimed at improving symptoms is recommended
over a treat-to-target strategy aimed at normalizing total
ALP in PDB.
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in the intravenous and intramuscular groups, respectively. Pain
had improved or disappeared in 21 of 27 (77%) of patients given
intravenous therapy at 6 months compared with 19 of 29
(65.5%) given intramuscular therapy, a difference that was not
signiﬁcant (chi-square 1.02, p¼ 0.30). Adverse effects in the two
treatment groups were similar. The authors concluded that both
routes of administration gave equivalent therapeutic responses
but commented that the intramuscular route was slightly more
expensive (115 versus 90 euros).
The evidence summary and recommendations with regard to
administering neridronate intravenously as opposed to intra-
muscularly are shown in Table 19.
Calcitonin
Calcitonin was one of the ﬁrst osteoclast inhibitors to be used
in the treatment of PDB. No randomized trials were identiﬁed
in which the effects of calcitonin were compared with placebo
or with other osteoclast inhibitors. One of the largest case
series of patients treated with calcitonin was published by
Martin and colleagues, who reported on the response to
porcine calcitonin 80 MRC units daily in a case series of 38
patients with active PDB who received 44 courses of treatment
by daily injection for periods of between 6 weeks and 18
months.(116) Bone pain improved in 32 of 38 (81.8%) patients
after treatment, although the method of assessing bone pain
was not described. Serum total ALP concentrations also
decreased from a mean (SEM) of 899 (145) U/L to 579 (130)
U/L (p< 0.001). The reference range for total ALP wasn’t
provided and so it was impossible to determine in what
proportion of patients total ALP values had fallen to within the
reference range. Six patients (15.7%) were reported to have
adverse effects, the most common of which were nausea and
diarrhea. In one patient (2.6%), treatment was stopped because
of adverse effects and in one (2.6%) the dose was reduced
because of adverse effects. Since these early reports, long-term
calcitonin therapy for osteoporosis has been associated with an
increased risk of certain cancers. We identiﬁed one randomized
trial of 44 patients with active PDB that had bone pain
inadequately unresponsive to analgesia who were randomized
to receive oral etidronate in a dose of 400mg daily for
6 months or oral etidronate 400mg daily plus calcitonin, 100 IU
three times weekly by subcutaneous injection.(117) The
response of biochemical markers of bone turnover in these
patients was compared with a group of historical controls with
PDB who had been treated with calcitonin alone at the same
dose. In the historical controls treated with calcitonin, total ALP
decreased from an average of 1261U/L before treatment to
595 U/L 6 months after treatment (53% reduction, p< 0.001).
Corresponding values for the etidronate group were 1228U/L
to 539U/L (56% reduction, p < 0.001) and for the etidronate
plus calcitonin group 1448U/L to 428 U/L (71% reduction,
p< 0.001). The combination of etidronate plus calcitonin was
more effective at decreasing total ALP than etidronate alone
(p< 0.002). The authors did not speciﬁcally comment on the
effects of these agents on bone pain in the results section.
Calcitonin has been studied in case series of patients with
neurological dysfunction associated with PDB and treatment
has been associated with clinical beneﬁt in some cases (Table
14).
The evidence summary and recommendations with regard to
the use of calcitonin in the treatment of metabolic activity and
pain in PDB are shown in Table 20.
Denosumab
There have been two case reports in the use of denosumab
60mg by subcutaneous injection every 6 months in PDB in
patients where bisphosphonates were poorly tolerated or
contraindicated. In both cases, denosumab resulted in a
decrease in total ALP concentrations and an improvement of
bone pain.(89,118) Three open-label trials have been conducted to
study the effects of denosumab in the treatment of GCT, but PDB
was an exclusion in two of these studies(119,120) and in the third,Table 19. Route of Administration of the Bisphosphonate
Neridronate in PDB
Risk-benefit balance
Information from randomized trials is only available for the
comparison of intravenous and intramuscular modes of
administration of neridronate. Both routes of administration
were found to give similar results in terms of suppression of
ALP and control of bone pain.
Quality of evidence
Low
Patient values and preferences
Improvements in bone pain are valued by patients. Some
patients might prefer two infusions as opposed to eight
intramuscular injections, although the intramuscular route
could be preferred in patients with poor venous access.
Costs and use of resources
Neridronate is inexpensive with little difference between
regimens. Nursing support costs may be higher with
intramuscular therapy, but day patient facilities and other
support costs may be higher with intravenous therapy.
Recommendation
For patients with metabolically active PDB with bone pain
treated with neridronate, either the intravenous or
intramuscular route can be recommended.
Table 20. Effects of Calcitonin on Bone Pain and Metabolic
Activity in PDB
Risk-benefit balance
Calcitonin improves bone pain in PDB and decreases total ALP
concentrations. Long-term administration of calcitonin has
been associated with an increased risk of cancer.
Quality of evidence
Very low
Patient values and preferences
Improvements in bone pain are highly valued by patients.
Adverse events may be observed with calcitonin, and the
need for repeated injections at frequent intervals may be
considered a barrier by some patients.
Costs and use of resources
Calcitonin is considerably more expensive than
bisphosphonates.
Recommendation
Calcitonin may be considered for the short-term treatment of
bone pain in PDB where bisphosphonates are
contraindicated.
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no information on co-existing PDB was available.(121) The
posology in this situation is an initial loading dose of 120mg
denosumab subcutaneously two times weekly followed by
120mg 4 times weekly thereafter. Of three case reports where
denosumabwas given to PDB patients with non-resectable GCT,
the treatment improved bone pain and reduced tumor
size.(122–124)
The evidence summary and recommendations with regard to
the use of denosumab in the treatment of PDB and GCT
associated with PDB are shown in Table 21.
Predicting the response to treatment in Paget’s disease
A large number of observational studies and clinical trials have
been conducted in which biochemical markers of bone turnover
have been measured before and after administration of various
bisphosphonates in PDB. Indeed, most clinical trials of
bisphosphonate therapy in PDB have used serum total ALP as
the primary endpoint for efﬁcacy.(66) These studies have
consistently shown that total ALP values and other biochemical
markers of bone turnover are decreased by bisphosphonate
therapy. It has been shown that the decrease is greater with
nitrogen-containing bisphosphonates as opposed to non-
nitrogen-containing bisphosphonates, and that within the
bisphosphonates, zoledronic acid is most effective at reducing
total ALP.(66)
Predicting the response of bone lesions
Al Nofal and colleagues conducted a systematic review and
meta-analysis of studies that compared changes in marker
concentrations after bisphosphonate therapy with disease
extent as assessed by quantitative radionuclide scintigraphy.(83)
Decreases in bone ALP concentrations after treatment have
been observed after treatment with various bisphosphonates.
However, in a meta-analysis, bone ALP was a weak predictor of
scintigraphic indices of disease extent after treatment (r¼ 0.24,
95% CI 0.004–0.457). Total ALP performed better than bone ALP
but with conﬁdence intervals that overlapped (r¼ 0.427, 95% CI
0.256–0.573), whereas PINP was the strongest predictor of
the bone formation markers assessed (r¼ 0.704, 95% CI 0.559–
0.808). The bone resorption markers ubCTX, sbCTX, uNTX, and
sNTX also signiﬁcantly predicted lesion extent assessed by
scintigraphy after bisphosphonate treatment with values of
0.563, 95% CI 0.297–0.748 for ubCTX; 0.639, 95% CI for sbCTX
0.401–0.796; and 0.674, 95% CI 0.518–0.787 for uNTX.
The evidence summary and recommendations with regard to
the use of biochemical markers in predicting the response of
bone lesions to bisphosphonate treatment in PDB are shown in
Table 22.
Predicting the response of bone pain
Boudreau examined the relation between changes in bone
pain in a series of 24 patients with PDB undergoing treatment
Table 21. Role of Denosumab in Paget’s Disease
Risk-benefit balance
From the evidence available, denosumab may be efficacious
treating pain and reducing tumor size in GCT complicating
PDB. There is little evidence supporting its use in PDB.
Quality of evidence
Very low
Patient values and preferences
Improvements in bone pain are highly valued by patients.
Patients may be dissuaded by the need for repeated
injections and risk of adverse events.
Costs and use of resources
Denosumab is considerably more expensive than
bisphosphonates and involves repeated injections
administered by a health care professional.
Recommendation
Denosumab may be considered for the treatment of GCT
complicating PDB when the tumor is nonresectable. There is
insufficient evidence to support the use of denosumab in the
treatment of PDB, and it is not recommended for this
indication.
Table 22. Predicting Response of Bone Lesions to Bisphosph-
onate Treatment
Risk-benefit balance
Biochemical markers of bone turnover can be easily assessed
by analysis of blood or urine samples, and several markers of
bone turnover are associated with scintigraphic extent of
bone lesions after bisphosphonate therapy.
Quality of evidence
Very low
Patient values and preferences
Patients may value undergoing biochemical tests to predict the
extent of PDB and response of bone lesions to
bisphosphonates.
Costs and use of resources
The strongest predictor was PINP, but the confidence intervals
overlapped with sbCTX, uNTX, and sNTX. These markers
performed better than total ALP but are more expensive and
not widely available.
Recommendation
Measurement of PINP is recommended to predict lesion extent,
as defined by scintigraphy, after bisphosphonate therapy.
Table 23. Predicting Response of Bone Pain to Bisphosphonate
Treatment
Risk-benefit balance
Biochemical markers of bone turnover can be easily assessed
by analysis of blood or urine samples, but these markers are
poorly associated with response of bone pain to osteoclast
inhibitors in PDB.
Quality of evidence
Very low
Patient values and preferences
Patients would value a test that could accurately predict the
response of bone pain to bisphosphonate therapy.
Costs and use of resources
Total ALP is an inexpensive marker. Other specialized markers
are considerably more expensive and not widely available.
Recommendation
Measurement of biochemical markers of bone turnover are not
recommended a means of predicting the response of bone
pain to osteoclast inhibitors in PDB.
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with etidronate, mithramycin, or calcitonin in relation to bone
scan appearances and changes in total ALP. They concluded
that changes in blood ﬂow as visualized on bone scan were
the most reliable predictor of response of pain, although
changes in total ALP and changes in bone scan static images
after treatment also were associated with the response of
pain.(125) This study is of limited relevance to modern-day
treatment of PDB in view of the agents employed. A
randomized placebo-controlled trial of alendronic acid per-
formed by Reid and colleagues(53) demonstrated that the
response of bone pain correlated poorly with reductions in
serum total ALP and urinary NTX. At baseline, all patients had
total ALP values at least twice the upper limit of normal, and
32 of 55 (58%) had pain thought to be due to PDB. After
treatment, serum total ALP and uNTX values decreased by 78%
and 86%, respectively, in the alendronic acid group but did not
change signiﬁcantly in the placebo group. Pain scores
decreased by a mean (SD) of –0.7 0.5 in the placebo and
–1.4 0.3 in the alendronic acid group, a difference that
was not signiﬁcant (p¼ 0.4). A randomized trial by Siris and
colleagues(112) compared biochemical responses with re-
sponses of bone pain in PDB patients randomized to
etidronate or risedronate sodium. All patients were required
to have a total ALP value at least twice the upper limit of the
reference range at baseline. At 6 months, ALP had decreased
by 63.4% in the risedronate sodium group and 17% in the
etidronate group (p< 0.001). The investigators reported that
change in pain scores adjusted for analgesic use at 6 months
showed no signiﬁcant difference between groups (p¼ 0.07). In
another randomized comparative trial of oral risedronate
sodium 30mg daily for 2 months and oral etidronate 400mg
daily for 6 months,(110) risedronate sodium normalized total
ALP in 73% of subjects at 6 months compared with 15% with
etidronate (p< 0.001). In this study, pain scores (assessed by
SF36) at 6 months reduced by about 3 points in the etidronate
group (not signiﬁcant) and 10 points in the risedronate sodium
group (p< 0.01). The difference in pain scores between the
groups (estimated by the 95% conﬁdence intervals displayed
on the graphs) was not signiﬁcant.
The evidence summary and recommendations with regard to
the use of biochemical markers in predicting the response of
bone lesions to bisphosphonate treatment in PDB are shown in
Table 23.
Predicting the response of other outcomes
There was no evidence upon which to identify predictors of
change in quality of life, progression of deafness, fractures, bone
deformity, or requirement for orthopedic surgery.
Effects of nonpharmacological treatments in Paget’s
disease
No randomized trials were identiﬁed that investigated the
effects of nonpharmacological treatments in PDB. The literature
review identiﬁed several observational studies and case reports
concerning the role of orthopedic surgery in PDB. Of these, we
only considered series where the sample size was 10 or greater.
No studies were identiﬁed that speciﬁcally investigated the role
of physiotherapy, occupational therapy, or other nonpharma-
cological interventions in the management of Paget’s disease.
Surgical management of fractures
No randomized trials were identiﬁed with regard to the
treatment of fractures in PDB, but the outcomes of surgical
treatment have been reported in several observational studies,
which for the most part, have been performed several decades
ago.
Table 24. Surgical Management of Fractures in PDB
Risk-benefit balance
The most commonly affected sites for fracture through Pagetic
bone are the femur and tibia. Surgery may be technically
difficult. Healing occurs normally in many patients, but the
clinical outcome in proximal femoral fractures is poor. The
benefit of fracture fixation in terms of pain relief and
mobilization is likely to outweigh the risks of surgery.
Quality of evidence
Very low
Patient values and preferences
Patients highly value a positive clinical outcome after fracture
fixation.
Costs and use of resources
The treatment costs for fracture fixation have not been
evaluated but are likely to be similar to those in patients
without PDB.
Recommendation
Surgery is recommended for fixation of fractures through
affected bone in PDB, but the clinical outcome in femoral
neck and subtrochanteric fractures is poor. There is
insufficient information to recommend one type of surgical
treatment over another.
Table 25. Total Knee and Hip Replacement for Osteoarthritis in
PDB
Risk-benefit balance
Total knee replacement (TKR) and hip replacement (THR) for
osteoarthritis can be performed successfully in many
patients with PDB with good results, although more data are
available for THR. Heterotopic calcification occurs in a high
proportion of patients undergoing THR and the risk of
aseptic loosening may be slightly higher than in non-Pagetic
patients. The benefit of surgery is likely to outweigh the risks
in most cases.
Quality of evidence
Very low
Patient values and preferences
Patients highly value the symptom relief and improvement in
quality of life that a hip replacement may offer.
Costs and use of resources
The treatment costs for TKR and THR in PDB are likely to be
similar to patients without PDB and this is recognized to be a
cost-effective option for patients with advanced
osteoarthritis.
Recommendation
Total hip or knee replacements are recommended for patients
with PDB who develop osteoarthritis in whom medical
treatment is inadequate. There is insufficient evidence to
recommend one type of surgical approach over another for
either site.
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Nicholas and colleagues evaluated clinical outcome of 23 PDB
patients with fractures of the femur through affected bone
referred to a specialist center for treatment.(126) Variousmethods
of treatment were used, including traction, intramedullary nails,
and plating. Only 11 of 23 (47.8%) patients were felt to have a
satisfactory outcome. Verinder evaluated clinical outcome of
89 fractures through affected bone in 67 patients with PDB who
were treated over a 15-year period in a single UK center.(127) The
femur was affected in 57 of 89 (64%) cases and the tibia in 22 of
89 (24.7%) and 10 of 89 (11.2%) in other sites. Various techniques
were used, including joint replacement, internal ﬁxation,
traction, and long leg plaster. Most healed satisfactorily, but
non-union occurred in 8 of 11 (72.2%) patients with femoral neck
fractures. Grundy(128) evaluated the clinical outcome in 63 low-
trauma femoral fractures through affected bone in 48 patients
presenting to a UK center over a 16-year period. Various
methods of management were used, including traction, plating,
and intramedullary nails. Most fractures healed satisfactorily, but
non-union occurred in 11 of 11 (100%) femoral neck fractures.
Bradley and Nade reviewed the outcome of 107 fractures of the
femur through affected bone in 93 patients with Paget’s disease
over a 25-year period from a center in New Zealand.(129) The
authors categorized subjects into those in whom the surgery
was successful and those in whom it was not (which they termed
failure). Failure was deﬁned to be present if there was non-union
if the implant failed or if revision surgery was required. Femoral
neck fractures had a high rate of failure (11 of 18 cases, 61.1%) as
did subtrochanteric fractures (17 of 36; 47.2%), whereas failure
was rare for fractures of the midshaft (1 of 24; 4.1%). Bidner and
Finnegan(130) reviewed the outcome of 35 femoral fractures
occurring through affected bone over an 8-year period in a
Canadian center. Variousmethods of internal ﬁxationwere used.
The authors commented that the results were generally
satisfactory but that with subtrochanteric fractures, non-union
occurred in 3 of 10 (30%) of cases.
The evidence summary and recommendations with regard to
surgical management of fractures in PDB are shown in Table 24.
Total hip replacement surgery
We identiﬁed three case series of total hip replacements for
osteoarthritis in patients with PDB. McDonald reviewed the
outcome of cemented total hip replacements for osteoar-
thritis in 80 patients undergoing 91 hip replacements treated
at a US referral center between 1969 and 1982.(131) The femur
was involved in 12 cases (13.2%), the acetabulum in 43 cases
(47.3%), and both sites in 36 cases (39.6%). Heterotopic
ossiﬁcation was observed after surgery in 34 of 91 hips (37%),
which the authors commented was much higher than
expected in patients without PDB (4.7%). Radiographic
evidence of prosthetic loosening was observed in 38 of 91
hips (41.7%). No association was observed between total ALP
levels at the time of surgery or preoperative drug treatment
with etidronate or calcitonin and the incidence of aseptic
loosening. Revision was required in 14 of 91 hips (15.3%). The
authors compared the likelihood of requiring revision for
aseptic loosening in the PDB group with a series of 7222
patients without PDB undergoing hip replacement at
the same center. There was no difference for up to 10 years,
but subsequently requirement for revision was greater in the
PDB subjects (approximately 40% compared with 5%,
p< 0.001). The authors commented that the results of
surgery were good or excellent in 74% of hips replaced.
Wegryzn reviewed the clinical outcome of 39 cementless hip
replacements in 32 patients undergoing surgery in a French
center between 1992 and 2006.(103) Heterotopic ossiﬁcation
occurred postoperatively in 22 of 39 hips (56%) and
prosthetic loosening in 6 of 39 hips (15.3%). No patient
had required revision surgery at the time of the review, which
occurred on average 133.5 months (range 97 to 194 months)
after surgery. Overall outcome (assessed by Harris hip score)
was reported to be excellent in 27 patients (84%) and fair in 5
(18%).
Parvizi(132) reviewed clinical outcome in 18 patients undergo-
ing 19 uncemented total hip replacements in a US referral center
between 1975 and 1996. In 18 of 19 (94%) cases, the serum total
ALP was normal at the time of surgery. The outcome as assessed
by Harris hip score was excellent in 16 cases (84.2%) and fair or
good in 3 (15.8%). Heterotopic ossiﬁcation occurred in 6 hips
(31.5%) and aseptic loosening in 2 hips (10.5%). None of the
patients had required revision surgery after an average
follow-up of 7.15 years (range 2 to 15).
Table 27. Spinal Surgery in PDB
Risk-benefit balance
Spine surgery can be performed successfully with good results
in patients with PDB. The benefit of surgery is likely to
outweigh the risks in most cases.
Quality of evidence
Very low
Patient values and preferences
Patients highly value the symptom relief and improvement in
neurological symptoms that spine surgery may provide.
Costs and use of resources
The treatment costs for spine surgery are considerable, but in
many cases the procedure may be cost-effective.
Recommendation
Spine surgery may be considered for patients with PDB who
develop spinal stenosis and spinal cord compression.
Table 26. Osteotomy
Risk-benefit balance
Osteotomy can be performed successfully with good results in
many patients with PDB of the femur and tibia with good
results. The benefit of surgery is likely to outweigh the risks
in most cases.
Quality of evidence
Very low
Patient values and preferences
Patients highly value the symptom relief that osteotomy may
provide in osteoarthritis.
Costs and use of resources
The treatment costs for osteotomy are likely to be lower than
those of a total joint replacement.
Recommendation
Osteotomy may be considered for patients with PDB who
develop osteoarthritis in whom medical treatment is
inadequate, but there is insufficient evidence to make a
recommendation on when this technique should be used as
opposed to other surgical procedures such as arthroplasty.
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Table 28. Summary of Recommendations
Investigation or indication Recommendation
Conditional
recommendation Insufficient evidence
Diagnosis of PDB
X-rays X-rays of abdomen, skull,
facial bone, and tibia
recommended
– –
Radionuclide bone scans To fully determine extent of
metabolically active disease
– –
MRI and CT Not recommended for
diagnosis
May be considered to
evaluate complications
–
ALP First-line biochemical test for
metabolically active PDB in
combination with LFT
– –
PINP, BALP, NTX – Second-line tests when
suspicion of metabolically
active disease is high and
ALP is normal
–
Bisphosphonate treatment
Bone pain Recommended for the
treatment of bone pain
– –
Quality of life – – Insufficient evidence;
treatment not recommended
Fracture prevention – – Insufficient evidence;
treatment not recommended
Progression of
osteoarthritis
– – Insufficient evidence;
treatment not recommended
Progression of hearing
loss
– – Insufficient evidence;
treatment not recommended
Blood loss during elective
orthopedic surgery
– – Insufficient evidence;
treatment not recommended
Bone deformity – – Insufficient evidence;
treatment not recommended
Neurological symptoms – Calcitonin or
bisphosphonates may be
considered as part of the
treatment package
–
Asymptomatic patients
with increased
metabolic activity
– Bisphosphonates may be
considered, but clinical
benefit unclear
–
Neoplastic transformation – – Insufficient evidence;
treatment not recommended
Adverse effects of
bisphosphonates
Patients can be reassured
about the favorable adverse
event profile
– –
Treatment strategy
Symptomatic or intensive
bisphosphonate
treatment
Treatment goal should be to
control bone pain rather than
normalize ALP
– –
Route of neridronate
administration
Intravenous and
intramuscular both
recommended
– –
Other treatments
Calcitonin for bone pain – May be considered for
short-term treatment of
bone pain
–
Denosumab for treatment
of PDB
– – Insufficient evidence;
treatment not recommended
Denosumab for giant cell
tumor
– May be considered for
treatment of giant cell
tumor that is unresectable
–
continued
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Total knee replacement surgery
Two case series of total knee replacement were identiﬁed.
Gabel(104) reviewed the outcome of total knee replacement
(TKR) in 13 patients who had 16 joint replacements referred
to a single US center between 1974 and 1986. Radiographic
loosening was observed in two cases and one patient
required revision surgery. The authors noted a functional
improvement after surgery with a mean preoperative score
of 33 points compared with 86 points postoperatively. They
concluded that knee replacement was an effective procedure
in patients with PDB. Lee reviewed the outcome of TKR in 21
knees from 20 patients with PDB undergoing treatment at a
US center between 1978 and 1999.(105) One patient required
revision surgery for aseptic loosening after an interval of
10 years. The authors reported that all patients were satisﬁed
with the procedures and felt that it had improved their
quality of life.
The evidence summary and recommendations with regard to
arthroplasty in the management of osteoarthritis in PDB are
shown in Table 25.
Osteotomy
Osteotomy is a recognized strategy for correction of bone
deformity and improvement of pain in PDB. We failed to identify
any studies in which osteotomy was compared with other
treatment modalities and so the GDG was unable make
recommendations on the role of this technique to be used as
opposed to other surgical approaches.
Parvizi(107) reviewed the outcome of 25 osteotomies in
22 patients with Paget’s disease referred to a single US center.
The indication for osteotomy was pain secondary to OA in
20 limbs, stress fractures in three, and deformity in two. The
most common site was the tibia (n¼ 16) followed by the femur
(n¼ 8) and radius (n¼ 1). Healing occurred in the vast majority
of procedures (23 of 25), with an average time to union of
6 months, but this was signiﬁcantly longer in metaphyseal
(average 240 days, range 120 to 360) than diaphyseal
osteotomies (average 150 days, range 60 to 360). Two patients
had delayed union. Patient satisfaction was reported as
excellent or good in 12 patients (60%), fair in 6 (30%), and
poor in 2 (10%).
Roper and colleagues(133) reviewed the results of osteotomy
of the intertrochanteric region of femur in 14 patients treated at
a single UK center. The indication for treatment was pain
associated with OA of the hip joint in all cases. The authors
reported that functional improvement had occurred in 12 of 13
(92.3%) patients and pain improved in 11 of 13 (84.6%), although
details of the method of assessment of pain and function were
not provided.
The evidence summary and recommendations with regard to
osteotomy in the management of osteoarthritis in PDB are
shown in Table 26.
Spinal surgery
Jorge-Mora and colleagues(106) conducted a systematic review
of patients undergoing surgical treatment of the spine in Paget’s
disease and identiﬁed 17 studies all of which described single
case reports. The most common indication for surgery was
spinal cord compression (n¼ 8), spinal stenosis (n¼ 6), and low
back pain. The most common procedure was laminectomy
(n¼ 12), although this was sometimes combined with other
surgical procedures. Improvement (full or partial) was noted to
occur in 14 of 17 cases.
The evidence summary and recommendations with regard
to spine surgery in the management of PDB are shown in
Table 27.
Table 28. (Continued)
Investigation or indication Recommendation
Conditional
recommendation Insufficient evidence
Predicting response to
treatment
Predicting response of
bone lesions
Measurement of PINP
recommended to predict
lesion extent defined by
scintigraphy after treatment
– –
Predicting response of
pain
Measurement of biochemical
markers is not recommended
as a means of predicting
response of bone pain
– –
Nonpharmacological
treatments
Fracture fixation Surgery is recommended for
fixation of fractures through
Pagetic bone
– –
Hip or knee arthroplasty Recommended for patients
with PDB with OA where
medical treatment is
inadequate
– –
Osteotomy – May be considered for
patients with PDB with OA
where medical treatment is
inadequate
–
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Summary
This guideline is the result of a comprehensive systematic review
on the diagnosis and management of PDB, which considered
both pharmacological and nonpharmacological treatment
options. A summary of the recommendations made are shown
in Table 28.
A graphical summary of the recommendations for diagnosis
and assessment of PDB is shown in Fig. 2 and for the
management of PDB in Fig. 3.
Fig. 2. Diagnosis and monitoring of Paget’s disease. ALP¼ total alkaline phosphatase; BALP¼bone-speciﬁc alkaline phosphatase; PINP¼procollagen
type I N-terminal propeptide; uNTX¼ urinary cross-linked N-terminal telopeptide of type I collagen.
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Although we have made recommendations in 12 areas and
conditional recommendations in ﬁve, the GDG noted that for
several outcomes of clinical importance to patients, there was
insufﬁcient evidence to answer the questions posed in this
guideline due to the fact thatmost clinical trials in PDB had been
short term and focused on biochemical markers as the primary
outcome, rather than patient-reported outcome measures.
Accordingly, the GDG felt that further research into PDB is
warranted and identiﬁed the following topics as areas where
research would be warranted (Table 29).
Fig. 3. Management of Paget’s disease.
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